Understanding genetic changes in appendiceal adenocarcinoma
Establishing the Repertoire of Actionable Alterations in Appendiceal Adenocarcinoma
This study is looking at the genes involved in a rare and tough cancer called appendiceal adenocarcinoma to help create a test that can find out which patients might do well with a special treatment that combines surgery and heated chemotherapy, aiming to improve treatment choices for those who don’t have many options right now.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project ID | NIH-11002645 on NIH RePORTER |
What this research studies
This research aims to uncover the genetic alterations associated with appendiceal adenocarcinoma, a rare and aggressive cancer. By analyzing patient tissue samples and clinical data, the study seeks to develop a genetic test that could identify patients who may benefit from a specific treatment called cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The research will also explore the genetic landscape of this cancer to improve treatment options and outcomes for patients. Ultimately, the goal is to enhance the eligibility for effective treatments for patients who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with appendiceal adenocarcinoma who may be eligible for CRS/HIPEC treatment.
Not a fit: Patients with appendiceal adenocarcinoma who are not candidates for surgery or those with very advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment pathways for patients with appendiceal adenocarcinoma, potentially improving survival rates.
How similar studies have performed: While research on appendiceal adenocarcinoma is limited, similar genetic approaches in other cancers have shown promise in improving treatment outcomes.
Where this research is happening
Winston-Salem, United States
- Wake Forest University Health Sciences — Winston-Salem, United States (Active)
Researchers
- Principal investigator: Miller, Lance David — Wake Forest University Health Sciences
- Study coordinator: Miller, Lance David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.